Hoth Therapeutics preclinical data shows GDNF reprograms liver fat metabolism
Hoth Therapeutics (NASDAQ:HOTH) announced on Tuesday, April 14, 2026, positive preclinical results for its HT-VA program, showing that parenteral administration of Glial Cell-Derived Neurotrophic Factor (GDNF) can fundamentally alter liver fat metabolism.











